On the flip side though, Sabina's project looks way better on an IRR and NPV basis than the Meliadine project from AEM (after-tax IRR of ~9% for Meliadine vs. Back River at 24% with 2x the NPV. It could be a nice buy vs. build scenario.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.